

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 November 2011 (03.11.2011)

PCT

(10) International Publication Number
WO 2011/137206 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2011/034244

(22) International Filing Date:
28 April 2011 (28.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/330,299 30 April 2010 (30.04.2010) US
61/379,197 1 September 2010 (01.09.2010) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOMEZ-MANCILLA, Baltazar** [MX/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HE, Yunsheng** [US/US]; Novartis Institutes for BioMedical Research, Inc., 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **JOHNS, Donald** [US/US]; Novartis Institutes for BioMedical Research, Inc., 220 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **MEYER, Joanne** [US/US]; Novartis Institutes for BioMedical Research, Inc., 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **PAULDING, Charles** [US/US]; 58 Whispering Brook Road, Groton, Massachusetts 01450 (US).

(74) Agent: **FISCHER, Leslie**; Novartis, One Health Plaza, Bldg. 101, East Hanover, New Jersey 07936 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS)

(57) Abstract: The invention is directed to the use of biomarkers to determine responsiveness of an individual with Fragile X Syndrome (FXS) to treatment with an mGluR5 antagonist.



WO 2011/137206 A1